Abstract
A 64-year-old man with prostate cancer and an increasing prostate-specific antigen (PSA) level under therapy with abiraterone acetate underwent a therapy with Ra. Before the first therapy and 4 weeks after the last cycle, the patient underwent Ga-PSMA PET, which showed a clear response of bone metastases.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Bone Neoplasms / radiotherapy*
-
Bone Neoplasms / secondary
-
Edetic Acid / analogs & derivatives
-
Gallium Isotopes
-
Gallium Radioisotopes
-
Humans
-
Male
-
Middle Aged
-
Oligopeptides
-
Organometallic Compounds
-
Positron-Emission Tomography / methods*
-
Prostate-Specific Antigen
-
Prostatic Neoplasms / pathology*
-
Radioisotopes / therapeutic use
-
Radium / therapeutic use*
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Gallium Isotopes
-
Gallium Radioisotopes
-
Oligopeptides
-
Organometallic Compounds
-
Radioisotopes
-
gallium 68 PSMA-11
-
Edetic Acid
-
Prostate-Specific Antigen
-
radium Ra 223 dichloride
-
Radium